Safety of Transesophageal Echocardiography in Patients with Prior Chest or Neck Irradiation. A Retrospective Cohort Study.

Osama Mahmoud (o_fahim@yahoo.com)
Geisinger Medical Center  https://orcid.org/0000-0003-4182-579X

Amro Alsaid
Geisinger Medical Center

Research

Keywords: Transesophageal echocardiography, Cardio-oncology, Safety of transesophageal echocardiography, Radiation therapy

DOI: https://doi.org/10.21203/rs.3.rs-21276/v1

License: ☕️ Ⓢ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Aims: Prior chest and neck irradiation are considered relative contraindications to transesophageal echocardiography. The foundation of such a warning is theoretical and, at best anecdotal. We intended to retrospectively examine the safety of transesophageal echocardiography in this cohort.

Methods and results: Utilizing the relevant International Classification of Diseases (ICD) and Current Procedural Terminology (CPT) codes, patients older than 18 years old with prior chest or neck irradiation therapy who underwent transesophageal echocardiography (TEE) at our institution in the period between 2004-2020 were identified and considered for inclusion. 31 patients, who underwent a total of 49 TEE studies, were included in the final analysis. In a 30 day follow up period following the index TEE, no significant complications occurred in any of the patients.

Conclusions: In this small cohort of patients with prior chest or neck irradiation therapy, transesophageal echocardiography was carried out safely and successfully.

Background

Transesophageal echocardiography (TEE) is an invaluable tool in evaluating cardiac structure and function with widespread applications in today's medical practice. It represents an important supplemental imaging modality to transthoracic echocardiography with superior accuracy in diagnosing certain valvular pathologies, intracardiac infections, and aortic pathology (1, 2). It also offers an alternative in patients with poor transthoracic imaging windows. The safety of TEE has been established with a very low risk of serious complications (1, 3, 4). Neck and mediastinal irradiation are considered a relative contraindication to TEE (5) due to a concern of radiation-induced tissue abnormalities that increase the risk of mechanical injuries in this cohort. However, the basis for such recommendation lacks, as does data on the safety of TEE in this patient population. We intended to investigate the safety and feasibility of TEE in patients with prior chest or neck irradiation.

Methods

Patient selection

Patients older than 18 years of age with a history of prior chest or neck irradiation and who have undergone transesophageal echocardiography at Geisinger Medical Center in the period between January 2004 and January 2020 were considered for inclusion. The relevant International Classification of Diseases (ICD) and Current Procedural Terminology (CPT) codes were used for data extraction. Patients who underwent upper gastrointestinal procedures within 4 weeks of the index TEE (nasogastric, orogastric and percutaneous gastrostomy, upper gastrointestinal endoscopy, esophageal stenting, esophageal and gastric surgeries), as well as patients with no 30-day, follow up (defined as the lack of medical encounters beyond the 30-day follow up period) were excluded.
Outcomes

The electronic records (clinical notes and radiological studies) were reviewed for occurrence of significant mechanical injuries to the pharynx, esophagus, and stomach defined as significant bleeding (more than 1 gram drop in hemoglobin), injuries requiring surgical repair or endoscopic intervention, hospital stay for observation, and death within 30 days of the index TEE.

Statistical analysis

Continuous variables are described via the use of mean and standard deviations from the mean, whereas categorical variables are described as proportions.

Results

Patient characteristics

6,752 TEE studies were done in the period between 1/2004 to 9/2019. Of these, 52 studies were done in 34 patients with prior chest or neck irradiation. Patients were identified utilizing the appropriate CPT and ICD codes. 2 patients were excluded due to the inability to locate the TEE information, and 1 patient was excluded due to the inability to confirm if radiation treatment was ever received. 31 patients, who underwent a total of 49 TEE examinations, were included in the final analysis (Fig. 1). The baseline characteristics are shown in Table 1.
Table 1
Baseline characteristics. SD: standard deviation. TEE: transesophageal echocardiography. cGy: centigray.

| Characteristic                                      | Mean (SD) value   |
|-----------------------------------------------------|-------------------|
| Mean (SD) age, year                                 | 71 (9.7)          |
| Female, n (%)                                       | 25 (80)           |
| Mean (SD) platelet count                            | 21 K/uL (9.8)     |
| Liver disease, n (%)                                | 0 (0)             |
| Systemic anticoagulation, n (%)                     | 16 (51.6)         |
| Dysphagia prior to TEE, n (%)                       | 3 (9.6)           |
| Mean (SD) time interval between radiation and TEE in years | 8 (10)          |
| Indication for TEE, n (%)                           | Intraoperative 24 (49), valve disease 15 (30), endocarditis 5 (10), intracardiac mass 3 (6), prior to cardioversion 2 (4). |
| Site of radiation therapy, n (%)                    | Breast 18 (58), mediastinum 5 (16), mantle 2 (6.4) lung 2 (6.4), larynx/tonsil 3 (10), chest wall 1 (3) |
| Mean (SD) total radiation dose in cGy \(^a\)         | 5441 (1466)       |
| Chemotherapy treatment, n (%)                       | 15 (48)           |
| Irradiation modality, n (%) \(^b\)                  | External beam 24 (78), brachytherapy 1 (0.03) |

\(^a\): data unavailable for 6 patients.

\(^b\): data unavailable for 6 patients.

18 (58\%) of our patients were treated with radiation therapy for breast cancer. Of which, 5 (16\%) patients had positive lymph node biopsies and thus received radiation to regional lymphatics (supraclavicular, internal mammary, or both). 8 (25.8\%) patients received combined chemoradiation. Tangential field radiotherapy was the utilized radiation modality in 10 (32\%) patients.

7 (22.5\%) patients underwent mediastinal or mantle radiation. 5 of which underwent combined chemoradiation therapy. Figure 2 depicts the sites of radiation therapy in our cohort. Figure 3 shows the total radiation dose received among the study subjects.

Details of the radiation therapy were not available in 6 patients.

Outcomes
49 studies were successfully performed in 31 patients, with no occurrence of significant complications in the 30-day follow up period.

**Discussion**

Radiation therapy (RT) is an integral treatment modality for several malignancies. The ionizing effects of radiation damage the DNA leading to cell death (6). Although aimed at malignant cells, normal cells are also susceptible to the damaging effects of RT. Side effects of RT is dependent upon tissue sensitivity and proximity to the radiation source, cumulative radiation dose, and concomitant chemotherapy. Adverse effects of RT stems from acute tissue swelling, secondary malignancies, and the long-term sequelae of tissue fibrosis (7–9). Neck radiation is known to cause lymphedema and tissue fibrosis in the long term (10). The likelihood of radiation-induced esophageal injuries is influenced by the radiation modality, total radiation dose to the esophagus, concurrent chemotherapy, and pre-existing esophageal diseases (11–15). Radiation doses in excess of 40–50 Gray (Gy) correlate with esophagitis risk (16). Radiation-induced esophageal injuries are commonly graded using the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) toxicity grading scale (17). In patients with non-small cell lung cancer (NSCLC) acute severe esophageal injuries had a reported incidence of 46% in one study (18) while only 3% had RTOG grade 3 late toxicity in another report (13). Esophageal strictures have been reported in pediatric patients, 10–15 years of age, after chest radiation for Hodgkin lymphoma (19, 20). The incidence of esophageal strictures in adults after radiotherapy for head and neck cancer was 3.3% in one report (21). NSCLC radiotherapy is also associated with the development of esophageal strictures (22).

The incidence of esophageal adverse effects with breast cancer radiotherapy is less well-studied. It is known, however, that there is an increased risk of esophageal cancer as second primary cancer in breast cancer survivors, and that risk is incremental with increasing radiation dose (23–25). Radiation doses to the esophagus are highest if supraclavicular and/or internal mammary lymph nodes were included in the treatment fields with a median dose of 25–38 Gy. Tangential fields resulted in significantly lower doses to the esophagus (less than 2 Gy) (24, 26).

The aforementioned late esophageal sequelae of radiation therapy pose a concern for higher risk of injuries with esophageal instrumentation, especially those done without direct visualization. Prior chest radiation is considered a relative contraindication to transesophageal echocardiography (5) however, the evidence supporting such recommendation is limited to case reports (27). In a meta-analysis of 22 studies, all perforations occurred in patients without perceivable risk factors (28). In another large single-center study, including 10,000 patients, 3 perforations occurred, none of which had risk factors, including chest radiation (29). Nevertheless, the safety of TEE in patients with prior chest radiation has never been systematically studied.

In our study 49 TEE examinations, in 31 patients, were performed successfully with no reported complications in a 30 day follow up period. The most frequent indication for TEE was intraoperative for
cardiac surgeries (Fig. 4). The median radiation dose was relatively high at 54 Gy (Fig. 3). The study included 16 patients with combined chemoradiation therapy, which infers a higher risk of esophageal adverse effects, none of which suffered significant complications.

The limitations of our study include a small sample size and possible selection bias, where only 3 patients (9.6%) had reported dysphagia/odynophagia. It is possible that patients with significant dysphagia were denied the procedure and can’t be accounted for in our conclusion. Another limitation of the study is the inclusion of 12 patients with lymph node-negative breast cancer who may not have received a significant radiation dose to the esophagus given the use of tangential fields and the exclusion of regional lymphatics from the radiation field (24, 26).

**Conclusion**

In a small cohort of patients with prior chest or neck irradiation, transesophageal echocardiography may be done safely and successfully in well-screened patients. Although more investigations, including larger sample sizes, are needed to determine the risk more accurately, our study suggests that transesophageal echocardiography doesn't carry a high risk of complications in patients with prior chest or neck irradiation.

**Abbreviations**

ICD
international Classification of Diseases
CPT
current Procedural Terminology code
TEE
transesophageal echocardiography
RT
radiation therapy
Gy
Gray
cGy
centigray
RTOG
Radiation Therapy Oncology Group
EORTC
European Organization for Research and Treatment of Cancer
NSCLC
non-small cell lung cancer

**Declarations**
Ethics approval and consent to participate:

Our study was approved by Geisinger medical center institutional review board.

Consent for publication:

Not applicable.

Availability of data and materials:

The data that support the findings of this study are available from Geisinger research institute, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of Geisinger research institute.

Competing interests
The authors declare that they have no competing interests.

Funding:
This study was funded by an internal grant provided by Geisinger Center for Health Research.

Authors' contributions:
OM prepared the study’s protocol, guided data extraction, reviewed individual charts, analyzed the data, and prepared the manuscript. AA supervised data analyses and assisted in preparing and proof-reading the manuscript. All authors read and approved the final manuscript.

Acknowledgments
We thank Mallory Snyder for her excellent help in coordinating this project and Ciaran Fisher for his assistance in data extraction and review.

References

1. Otto CM. Clinical Indications and Quality Assurance. In: Textbook of Clinical Echocardiography, 4th edition, Saunders Elsevier, 2009. p. 117–118.

2. American Society of Echocardiography, American Heart Association /SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force -Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, Picard MH, Polk DM, Ragosta M, Ward RP, Weiner RB. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association. American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic
Resonance Endorsed by the American College of Chest Physicians. J Am Coll Cardiol. 2011;57(9):1126.

3. Min JK, Spencer KT, Furlong KT, DeCara JM, Sugeng L, Ward RP, et al. Clinical features of complications from transesophageal echocardiography: a single-center case series of 10,000 consecutive examinations. J Am Soc Echocardiogr. 2005;18:925–9.

4. Sainathan S, Andaz S. A systematic review of transesophageal echocardiography-induced esophageal perforation. Echocardiography. 2013;30:977–83.

5. Hahn RT, Abraham T, Adams MS, Bruce CJ, Glas KE, Lang RM, Reeves ST, et al. Guidelines for performing a comprehensive transesophageal echocardiogram examination: Recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr. 2013;26:921–64.

6. Revell SH. Relationship between chromosome damage and cell death, Liss A, editor, New York City 1983. p. 113.

7. Suit H, Goldberg S, Niemierko A, Ancukiewicz M, Hall E, Goitein M, Wong W, Paganetti H. Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res. 2007 Jan;167(1):12–42.

8. Haase O, Rodemann HP. Fibrosis and cytokine mechanisms: relevant in hadron therapy? Radiother Oncol. 2004;73(Suppl 2):144.

9. Delanian S, Porcher R, Rudant J, Lefaix JL. Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol. 2005;23(34):8570. Epub 2005 Oct 31.

10. Deng J, Murphy BA, Dietrich MS, Wells N, Wallston KA, Sinard RJ, Cmelak AJ, Gilbert J, Ridner SH. Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life. Head Neck. 2013 Jul;35(7):1026–35. Epub 2012 Jul 12.

11. Seaman WB, Ackerman LV. The effect of radiation on the esophagus; a clinical and histologic study of the effects produced by the betatron. Radiology. 1957;68(4):534.

12. Morichau-Beauchant M, Touchard G, Battandier D, Maire P, Fontanel JP, Daban A, Babin P, Matuchansky C. Chronic radiation-induced esophagitis after treatment of oropharyngolaryngeal cancer: a little-known anato-mono-clinical entity. Gastroenterol Clin Biol. 1983;7(11):843.

13. Maguire PD, Sibley GS, Zhou SM, Jamieson TA, Light KL, Antoine PA, Hemdon JE 2nd, Anscher MS, Marks LB. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 1999;45(1):97.

14. Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55(2):337.

15. Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential...
and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of
the lung. Int J Radiat Oncol Biol Phys. 1998;42(3):469.

16. Werner-Wasik M, Yorke E, Deasy J, Nam J, Marks LB. Radiation dose-volume effects in the
esophagus. Int J Radiat Oncol Biol Phys. 2010;76(3):86–93.

17. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the
European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys.
1995;31:1341–6.

18. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T. Multiinstitutional
phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-
small-cell lung cancer. J Clin Oncol. 1998;16:3316–22.

19. Ellenhorn JD, Lambroza A, Lindsley KL, LaQuaglia MP. Treatment-related esophageal stricture in
pediatric patients with cancer. Cancer. 1993;71:4084–90.

20. Mahboubi S, Silber JH. Radiation-induced esophageal strictures in children with cancer. Eur Radiol.
1997;7:119–22.

21. Alevronta E, Ahlberg A, Mavroidis P, al-Abany M, Friesland S, Tilikidis A, et al. Dose-response relations
for stricture in the proximal oesophagus from head and neck radiotherapy. Radiother Oncol.
2010;97:54–9.

22. Ahn SJ, Kahn D, Zhou S, Yu X, Hollis D, Shafman TD, et al. Dosimetric and clinical predictors for
radiation-induced esophageal injury. Int J Radiat Oncol Biol Phys. 2005;61:335–47.

23. Zablotska LB, Chak A, Das A, Neugut AL. Increased risk of squamous cell esophageal cancer after
adjuvant radiation therapy for primary breast cancer. Am J Epidemiol. 2005;161(4):330–7.

24. Morton LM, Gilbert ES, Hall P, Andersson M, Joensuu H, Vaalavirta L, Dores GM, Stovall M, Holowaty
EJ, Lynch CF, Curtis RE, Smith SA, Kleinerman RA, Kajser M, Storm HH, Pukkala E, Weathers RE, Linet
MS, Rajaraman P, Fraumeni JF Jr, Brown LM, van Leeuwen FE, Fossa SD, Johannesen TB, Langmark
F, Lamart S, Travis LB, Aleman BM. Risk of treatment-related esophageal cancer among breast
cancer survivors. Ann Oncol. 2012;23:3081–91.

25. Ahsan H, Neugut AI. Radiation therapy for breast cancer and increased risk for esophageal
carcinoma. Ann Intern Med. 1998;128(2):114–7.

26. Lamart S, Stovall M, Simon SL, Smith SA, Weathers RE, Howell RM, Curtis RE, Aleman BM, Travis L,
Kwon D, Morton LM. Radiation dose to the esophagus from breast cancer radiation therapy, 1943–
1996: An international population-based study of 414 patients. Int J Radiat Oncol Biol Phys.
2013;86:694.

27. Brinkman WT, Shanewise JS, Clements SD, Mansour KA. Transesophageal echocardiography: not an
innocuous procedure. Ann Thorac Surg. 2001;72:1725–6.

28. Sainathan S. Andaz S. A systematic review of transesophageal echocardiography-induced
esophageal perforation. Echocardiography 2013;30:977–83.

29. Hilberath JN, Oakes DA, Sherman SK, Bulwer BE, D'Ambra MN, Eltzschig HK. Safety of
transesophageal echocardiography. J Am Soc Echocardiogr. 2010;23(11):1115–27.
Figure 1

Patient selection and inclusion.
Figure 2

Sites of radiation therapy in the study patients.
Figure 3

Total radiation dose in cGy received per patient in the study population.
Figure 4

Indications for transesophageal echocardiography.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- **Coverletter.docx**